- The first patient was dosed in the Phase 1b/2a dose escalation trial of KINE-101.This
study is conducted in Korea in patients with CIDP who have
received at least one frontline treatment regimen.
- Kine Sciences advanced KINE-101 to the Phase 1b/2a study following the successful completion
of a Phase 1 study in the US.
- KINE-101 is a disease modifier nanopeptide that acts by
activating Treg cells.
SEOUL,
South Korea, Sept. 13,
2024 /PRNewswire/ -- Kine Sciences, a
clinical-stage, biopharmaceutical company developing small
peptides for immune-mediated diseases, announced that the first
patient has been dosed in its Phase 1b/2a clinical study of KINE-101 for CIDP.
"Dosing the first patient marks our first programme in the
clinic and represents an important milestone for our company." said
Dae Ho Cho, PhD, Chief Executive
Officer. "We look forward to the clinical data that will support
the strong efficacy that we have seen in the preclinical studies.
KINE-101 has a unique mechanism of action that targets what we
believe is an underlying cause of the disease and differentiates it
from symptomatic treatments. Moving forward, KINE-101 has the
potential to offer more effective treatment options for CIDP
patients either as a standalone therapy or in combination with
existing treatments."
KINE-101 is a novel nanopeptide and a disease modifier that
controls both humoral immunity and cell-mediated immune responses
by activating Treg cells. KINE-101 received FDA clearance for the
Phase I study on September, 2021. The study was conducted in 40
healthy individuals in five cohorts assessed over 42 days. The
design included four cohorts receiving intravenously administered
ascending doses of KINE-101 (10, 30, 100, and 300 mg), and a cohort
that received 96.8 mg of KINE-101 subcutaneously. The Phase 1 study
was completed successfully on October, 2023 demonstrating an
excellent safety profile. Beyond CIDP, KINE-101 is in development
for additional indications, including Inflammatory Bowel Disease,
Rheumatoid Arthritis and Non-Alcoholic Steatohepatitis.
About Kine Sciences
Kine Sciences was founded in 2016. It is a clinical-stage,
biopharmaceutical company developing ultra small size peptides for
a range of immune-mediated diseases based on functional immunomics.
The company's peptides derive from a novel anti-inflammatory
cytokine that targets different immune cells. Kine Sciences'
approach and the ultra-small size of the peptides offers clear
advantages such as a favourable pharmacokinetic vs pharmacodynamic
profile, low immunogenicity, low antigenicity, low production costs
and potential for oral administration. Beyond KINE-101, the company
is advancing several novel candidates through preclinical studies
across different indications. For more information, on the company
and its pipeline visit the Kine Sciences website at
http://kinesciences.com/.
Forward-Looking Statements
Statements in this press release that are not purely
historical are forward-looking statements. Such forward-looking
statements include, among other things, references to Kine
Sciences' product candidates, including KINE-101, and its
development and clinical trial milestones such as the expected
trial design, timing of patient enrollment, patient dosing, data
readouts, and the therapeutic potential thereof. Actual results
could deviate from those projected in any forward-looking
statements due to several factors. Such factors include, among
others, the company's ability to raise the necessary funding to
continue to pursue its business and product development plans, the
inherent risk associated with developing novel therapeutic agents
and operating as a development stage company, the company's ability
to develop, complete clinical trials for, obtain approvals for and
commercialize any of its product candidates, competition in the
industry in which the company operates, and market conditions.
These forward-looking statements are made as of the date of this
press release. Unless otherwise required by applicable laws, Kine
Sciences does not intend, nor does it undertake any obligation, to
update or revise any forward-looking information to reflect
subsequent information, events, results, circumstances or
otherwise. Accordingly, the reader is cautioned not to place undue
reliance on forward-looking information.
BD & Investor Contact:
Kyriakos
Tzafestas,
kyriakos@pharmaventures.com
+44 (0)7387 101 284
Ju Yeon Lee,
jylee@kinesciences.com
View original
content:https://www.prnewswire.com/news-releases/kine-sciences-announces-first-patient-dosed-in-the-phase-1b2a-study-in-patients-with-chronic-inflammatory-demyelinating-polyneuropathy-cidp-302246634.html
SOURCE Kine Sciences